FDA Shuts Down Emergency Use for Major COVID Antibody Drugs
Published Date: 7/29/2025
Notice
Summary
The FDA has officially ended the emergency use of several COVID-19 antibody treatments from Regeneron, GSK, Lilly, and AstraZeneca as of December 13, 2024. This means these drugs can no longer be used under emergency rules, affecting patients and healthcare providers relying on them. The change reflects updated safety and effectiveness info, so folks should look for other treatment options moving forward.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
EUA Revoked for Four COVID Antibodies
On December 13, 2024, the FDA revoked the Emergency Use Authorizations for REGEN-COV (casirivimab and imdevimab), sotrovimab, bebtelovimab, and EVUSHELD (tixagevimab co-packaged with cilgavimab). This means these drugs can no longer be used under emergency rules and may affect patients and health care providers who relied on them.
Revocations Cited Safety/Effectiveness; Find Alternatives
The FDA said the revocations reflect updated safety and effectiveness information and advises people who used or would have used these treatments to look for other treatment options going forward. The revocations took effect December 13, 2024.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-14232 — Freight Rail Couplers and Parts Thereof From Czech Republic and India; Institution of Antidumping and Countervailing Duty Investigations and Scheduling of Preliminary Phase Investigations
The U.S. is launching investigations to see if freight rail couplers from the Czech Republic and India are being unfairly sold or subsidized, which might hurt American businesses. If problems are found, extra taxes could be added to these imports. The first big decision is due by September 8, 2025, so things are moving fast!
Next: 2025-14234 — Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Notice of Filing of Proposed Rule Change To Amend the Hashdex Nasdaq Crypto Index US ETF To Allow for In-Kind Transfers Under Nasdaq Rule 5711(d) (Commodity-Based Trust Shares)
Nasdaq wants to update the Hashdex Nasdaq Crypto Index US ETF so it can swap bitcoin and ether 'in-kind' instead of just cash. This change helps investors trade more smoothly and could save money on fees. The new rule is up for review now and, if approved, will make crypto ETF trading easier and more efficient starting soon.